Business
Cognition Therapeutics Announces Participation in September Investment Conferences
PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today announced that members of management will be participating in two investment conferences in September 2022. Details of the presentations are as follows: Conference: H.C. Wainwright 24th Annual Global Investment ConferencePresentation Date: September 14, 2022Presentation Time: 10:30am – 11:00am ETLocation: Lotte New York Palace, New York City Conference: Ladenburg Thalmann Healthcare Conference 2022Presentation Date: September 29, 2022Presentation Time: 1:30pm – 1.55pm ETLocation: Sofitel Hotel, New York City Live and archived webcasts for each conference will be available on the Investors section of the company’s website at https://ir.cogrx.com. In addition, the Cognition management team will be available for one-on-one meetings during the conferences. Registered investors will be able to request a meeting with management via the conference portals. About Cognition Therapeutics, Inc.Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to p...